Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies
Luisa Chiapparini
Annals of Neurology, 2013
View PDFchevron_right
Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
Hayrettin Tumani
PLoS ONE, 2013
View PDFchevron_right
Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression
Cristiana Barbati
Autoimmunity Reviews, 2010
View PDFchevron_right
Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation
Milica Kramberger
Journal of Alzheimer's disease : JAD, 2016
View PDFchevron_right
Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition
Nikhil Thaker
Journal of Alzheimer's disease : JAD, 2011
View PDFchevron_right
Anti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: a case report
Laura Brighina
Neurology, 2011
View PDFchevron_right
Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients
B. Imbimbo
Future Neurology, 2012
View PDFchevron_right
Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Pierre Aucouturier
Frontiers in Immunology
View PDFchevron_right
Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity
YeQing Pi
Brain : a journal of neurology, 2015
View PDFchevron_right
Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: A putative marker of an ongoing inflammatory process
Lorenz Hirt, Judith Miklossy
Experimental Gerontology, 2007
View PDFchevron_right
Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy
Roxana Carare
Acta neuropathologica, 2014
View PDFchevron_right
Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
Leslie Shaw
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015
View PDFchevron_right
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Dubravka Švob Štrac
Croatian Medical Journal, 2014
View PDFchevron_right
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid
Ting Yang, Dominic Walsh
Alzheimer's Research & Therapy, 2015
View PDFchevron_right
Passive antiamyloid immunotherapy for Alzheimerʼs disease
Marcia Radanovic
Current Opinion in Psychiatry, 2020
View PDFchevron_right
Early Detection of Alzheimer’s Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers
George Godsey
Journal of Alzheimer's Disease
View PDFchevron_right
Current state of Alzheimer’s fluid biomarkers
Gary Tong
Acta Neuropathologica
View PDFchevron_right
Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide
Yansheng Du
Biological Psychiatry, 2005
View PDFchevron_right
Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
Rawan Tarawneh
CNS & Neurological Disorders - Drug Targets, 2009
View PDFchevron_right
Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies
Leslie Shaw
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2014
View PDFchevron_right
Amyloid-β Immunotherapy for Alzheimer Disease: Is It Now a Long Shot
Madia LOZUPONE
View PDFchevron_right
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
inge lues
Molecules (Basel, Switzerland), 2018
View PDFchevron_right
Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- 1-42 and Proteins as Alzheimer Disease Biomarkers
Jon Toledo, Magdalena Korecka
Clinical Chemistry, 2013
View PDFchevron_right
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
Kunal Dhiman
Cellular and Molecular Life Sciences
View PDFchevron_right
Intracerebroventricular amyloid- antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice
Lisa Shafer
Proceedings of the National Academy of Sciences, 2009
View PDFchevron_right
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Marta Milà Alomà
Therapeutic Advances in Neurological Disorders
View PDFchevron_right
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation
Roberto Marconi
Neurology, 2021
View PDFchevron_right
Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease
Niklas Mattsson
NeuroMolecular Medicine, 2012
View PDFchevron_right
Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation
Rebecca Koscik
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2015
View PDFchevron_right
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.
Abedelnasser Abulrob
View PDFchevron_right
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
Andrea Santamato
Expert Review of Clinical Immunology, 2014
View PDFchevron_right
Cerebrospinal Fluid Markers of Alzheimer's Disease
W. Van Gool
Journal of the American Geriatrics Society, 1991
View PDFchevron_right
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)
Kewei Chen
Alzheimer's research & therapy, 2018
View PDFchevron_right
Immune complexes of auto-antibodies against Aβ1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients
Andreas Henkel
Molecular Psychiatry, 2007
View PDFchevron_right